Plain-English translation of NCT06635148 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a follow-up study for people who already received , an experimental gene therapy injected directly into the eye to treat geographic atrophy — a serious form of age-related vision loss. Researchers want to track how safe this medication is over the long term and watch for any delayed side effects in people who have already been treated.
Gene therapies are new, and doctors need to understand if this treatment remains safe months and years after a single injection. This study will help researchers learn whether the medication causes any problems that develop slowly over time.
You likely qualify if…
You likely don't qualify if…
You will not receive any new injections or treatments as part of this follow-up study. Instead, you will return for regular clinic visits where doctors will examine your eye and check for any side effects or changes in your vision. The study simply monitors your health over time to make sure the earlier treatment remains safe.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States